RESPONSE
Dear colleagues,
We agree with your analysis and believe that a higher circulation of the criteria of eligibility to the extracorporeal treatment, both for the treatment of severe cases of ARDS and for refractory shock, could lead to a greater number of patients treated and therefore saved.
However we cannot forget the serious economic crisis that part of Europe is suffering, and the remarkable cut of the financial resources that seriously limits the possibility to carry out programs of widespread awareness campaign. Despite these hard limitations, other initiatives continue. A web-based interface for information (www.ecmonet.org) is continuously updated. A 24/24 hours and 7/7 days telephone Help-line ( 800 - 82 12 29 ) is always active in Italy for any kind of information and assistance. In engaging ourselves to keep alive the interest of the scientific community and looking forward to a “consensus conference” that will establish guidelines, we propose, as follows, the criteria of inclusion to the extracorporeal therapy.
Pathological Processes Suitable for venous-venous (V-V) ECMO
Severe pneumonia
ARDS
Acute lung (graft) failure following transplant
Pulmonary contusion
-
Others:
- Alveolar proteinosis
- Smoke inhalation
- Status asthmaticus
- Airway obstruction
- Aspiration syndromes
Respiratory Indications to V-V ECMO (after considering recruitment maneuvers, conventional or HFO protective lung ventilation, prone positioning, diuresis or renal replacement therapy for correction of volume overload, optimization of perfusion including restoration of oncotic pressure, intravascular volume, and inotropes). Identify acute reversible pulmonary injury and select patients early in the course.
Murray score >3
PaO2/FIO2 <100 (mm Hg) despite high PEEP (10 -20 cmH2O) on FiO2 >80%
-
Others:
- Intrapulmonary right-to-left shunt (Qs/QT) >30%
- Total thoracopulmonary compliance (CTstat) <30 ml/cmH2O
- Severe hypercapnia with PaCO2 >80 on FiO2 >90% or pH <7.20
- Maximal medical therapy >48 h
Contraindication to V-V ECMO
Absolute
Irreversible cardiac or pulmonary disease
Metastatic malignancy
Significant brain injury
Current intracranial hemorrhage
Major pharmacologic immunosuppression (absolute neutrophil count <400 )
Relative
Age >65-70 years, considering increasing risk with increasing age
Mechanical ventilation at high settings (FiO2 >90%, Plateau Pressure >30) >7-10 days
Multitrauma with high risk of bleeding
Pathological Processes Suitable for venous-arterial (V-A) ECMO
Cardiogenic shock: Acute Myocardial Infarction and complications (including: wall rupture, papillary muscle rupture, refractory ventricular tachycardia or fibrillation) refractory to conventional therapy including intraaortic balloon pump
Post cardiac surgery: unable to wean safely from cardiopulmonary bypass using conventional supports
Drug overdose with severe cardiac depression
Myocarditis
Early graft failure: post heart/heart-lung transplant
-
Others:
- Pulmonary embolism
- Cardiac or major vessel trauma
- Massive hemoptysis/pulmonary hemorrhage
- Pulmonary trauma
- Acute anaphylaxis
- Peri-partum cardiomyopathy
- Sepsis with severe cardiac depression
- Bridge to transplant
Cardiac Indications to V-A ECMO (shock persist despite volume administration, maximal inotropic and vasoconstrictors support, mechanical ventilation and intra-aortic balloon counterpulsation - if appropriate -)
Cardiac index <2 L/min/m2
Lactate level >50 mg/dl or 5 mmol/L or Central Venous Oxygen Saturation - ScVO2 <65% with maximum medical management
-
Others:
- Systolic blood pressure less than 90 mmHg
- Low cardiac output
Contraindication to V-A ECMO
Absolute
Unrecoverable heart and not a candidate for transplant or Ventricular Assist Device (VAD)
Age >75 years
Chronic organ dysfunction (Emphysema, cirrhosis, renal failure)
Prolonged Cardiopulmonary Resuscitation without adequate tissue perfusion
Aortic dissection
Severe aortic valve regurgitation
Current intracranial hemorrhage
Extracorporeal Cardiac Life Support (ECLS) - Extracorporeal Cardiopulmonary Resuscitation (ECPR)
Indications to V-A ECMO include persistent cardiopulmonary arrest despite traditional resuscitative efforts.
ECLS-ECPR Contraindications to V-A ECMO
Initial rhythm asystole
Age >80 years
Chest compressions not initiated within 10 min of arrest (either bystanders or emergency medical team)
Cardiopulmonary Resuscitation >60 min before implanting ECMO
Pre-existing severe neurological disease (including traumatic brain injury, stroke, or severe dementia)
Current intracranial hemorrhage
Malignancy in the terminal stage
Cardiac arrest of traumatic origin with uncontrolled bleeding
Irreversible organ failure leading to cardiac arrest when no physiological benefit could be expected despite maximal therapy
Alberto Zangrillo
Professor of Anesthesiology and Intensive CareUniversità Vita-Salute San Raffaele, Milan
Footnotes
Source of Support Nil.
Conflict of interest None declared.
Cite as: Zangrillo A. The criteria of eligibility to the extracorporeal treatment. HSR Proceedings in Intensive Care and Cardiovascular Anesthesia 2012; 4 (4): 271-273
References
- Pappalardo F, Pieri M, Greco T. et al. Predicting mortality risk in patients undergoing venovenous ECMO for ARDS due to Influenza A (H1N1) pneumonia: the ECMOnet score. Intensive Care Med. 2012 doi: 10.1007/s00134-012-2747-1. [In press] [DOI] [PMC free article] [PubMed] [Google Scholar]
- Patroniti N, Zangrillo A, Pappalardo F. et al. The Italian ECMO network experience during the 2009 influenza A(H1N1) pandemic: preparation for severe respiratory emergency outbreaks. Intensive Care Med. 2011;37:1447–1457. doi: 10.1007/s00134-011-2301-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Peek GJ, Mugford M, Tiruvoipati R. et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet. 2009;374:1351–1363. doi: 10.1016/S0140-6736(09)61069-2. [DOI] [PubMed] [Google Scholar]
